Advertisement

Disseminated Intravascular Coagulation in the Obstetric Patient

  • S. Mangione
  • A. Giarratano
Conference paper

Abstract

Disseminated intravascular coagulation (DIC) has been suggested to be a syndrome rather than a disease. This syndrome is often connected to a systemic pathology and is always secondary to an underlying disease. DIC is characterised by a systemic activation of coagulation system, with the generation and deposition of fibrin and microvascular thrombi in various organs. It is a systemic thrombohaemorrhagic disorder associated with a well-defined clinical situation, laboratory evidence of procoagulant activation, fibrinolytic activation, inhibitor consumption and biochemical evidence of end-organ dysfunction [1, 2, 3].

Keywords

Disseminate Intravascular Coagulation Disseminate Intravascular Coagulation Recurrent Pregnancy Loss HELLP Syndrome Procoagulant Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bick LR (1995) Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin. Appl. Thromb. Hemostas. 1: 3–23CrossRefGoogle Scholar
  2. 2.
    Bick LR, Murano G (1994) Physiology of hemostasis Clin Lab Med 14: 677–708.Google Scholar
  3. 3.
    Brozovic M (1987) Disseminated intravascular coagulation. In: Haemostasis and Thrombosis Churchill-Livingstone, pp: 535–541Google Scholar
  4. 4.
    Corrigan JJ (1968) Changes in the blood coagulation system associated with septicaemia. N Engl J med 279: 851–856PubMedCrossRefGoogle Scholar
  5. 5.
    Bick LR (1998) Pathophysiology of DIC Sem Thromb Hemostas 24: 3–18CrossRefGoogle Scholar
  6. 6.
    Okaijma K, Uchiba M (1998) The anti-inflammatory properties of AtIII: new therapeutic implications in severe sepsis. Sem Thromb Hemostas 24: 3–18CrossRefGoogle Scholar
  7. 7.
    Horie S, Ishi H, Kazama M (1990) Heparin-like glycosoaminoglican is a receptor for AtIII dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 59: 895PubMedCrossRefGoogle Scholar
  8. 8.
    Hoffman M, Cooper ST (1995) Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 by two distinct mechanism. Blood Cells Molec Dis 21: 156–167PubMedCrossRefGoogle Scholar
  9. 9.
    Gore M, Eldon S, Trofatter KF et al (1987) Pregnancy induced changes in the fibrinolytic balance evidence for defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor. Am J Obst Gynecol 156: 674–680.Google Scholar
  10. 10.
    Paternoster DM, Stella A, Simioni P, et al (1996) Fibronectin and antithrombin as markers of preeclampsia in pregnancy Europ J Obst Gyn Reprod Biol, 70: 33–39CrossRefGoogle Scholar
  11. 11.
    Reister F, Heil W, Rath W (1997) Coagulation disorders in Obstetrics. Biom Progr 10: 62–67.Google Scholar
  12. 12.
    Redman CWG, Sacks GP, Sargent IL. (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy Am J Obstet Gynecol 180: 499–506PubMedCrossRefGoogle Scholar
  13. 13.
    Mangione S, Giarratano A, Leone I, Mangione D (1996) Monitoraggio e trattamento delle coagulopatie in ostetricia ad alto rischio. Min Anes 62: 623–626.Google Scholar
  14. 14.
    Gilabert J, Fernandez JA, Espana F, et al (1988) Physiological coagulation inhibitors (protein C, protein S and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb. Res. 49: 319–329.PubMedCrossRefGoogle Scholar
  15. 15.
    Giarratano A, Cuccio G, Mangione S (2000) Effects of AT III treatment (high doses) in severe pre-eclampsia and HELLP syndrome with alterations of coagulation inhibitors and inflammatory markers: a preliminary report. Crit Care 4:sl7CrossRefGoogle Scholar
  16. 16.
    Gando S, Kameue T, Nanzaki S, Nakanishi Y (1995) Cytochines, soluble thrombornodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 80: 519–526PubMedCrossRefGoogle Scholar
  17. 17.
    Stormorken H (1979) Interrelationship between coagulation, the fibrinolytic and the kallikrein and kinin system.Scandin J Hematol 34: 24–27Google Scholar
  18. 18.
    Maki M, Takao K, Terao T, et al (2000) Atithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thromb Hemost; 84: 583–90Google Scholar
  19. 19.
    Esmon CT (2001) The normal role of activated Protein C in maintaining homeostasis and its relevance to critical illness. Crit care 5:S7–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Giarratano A, Capogna G, Celleno D, et al (2000) A new approach in the treatment of severe preeclampsia and HELLP syndrome using high doses of Antithrombin III. 26s3:S321–417Google Scholar

Copyright information

© Springer-Verlag Italia 2002

Authors and Affiliations

  • S. Mangione
    • 1
  • A. Giarratano
    • 1
  1. 1.Department of Anaesthesiology and Intensive CarePalermo UniversityPalermoItaly

Personalised recommendations